The<unk>  (ERT) uses the estrogen<unk>  (ER) tumor marker that allows for immunohistochemical techniques to be performed for diagnostic purposes. Immunohistochemistry (IHC) techniques involve the selective identification of antigen proteins by exploiting these antigen-antibody relationships to characterize your analyte of interest. Previously, the ligand binding assay has been used in the determination of ER activity, however this method was limited because of the requirement of large quantities of fresh tissue needed for each assay. IHC serves as a more efficient methods as this technique allows for the morphology of the tissue to be observed in a tumor-specific manner. This increases the practicability of this technique as in many cases, patients’ tissue samples are limited in the applications of biomarker analysis. Anti-estrogen<unk>  antibodies were among the first of biomarkers which introduced a semi-quantitative assessment of the ER activity. Today, ER analysis is one of many routinely performed immunohistochemical assays performed to classify the hormone<unk>  status and to serve as a means of insight in the determination of cancer prognosis and management.
Estrogen receptor test
Estrogen provocation test
Breast ultrasound
Breast MRI
Cytopathology
Breast imaging
Breast duct endoscopy
Breast biopsy